Ever since antibody drug conjugates (ADCs) were first reported in the 1970s, the field of bioconjugation has found itself in a constant state of evolution.
Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO...
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
Swiss CDMO Lonza has acquired Dutch-based Synaffix, a biotech focused on ADC development. The deal comprises an initial cash injection of €100 million and up to €60...
The new PBPK modelling service from Lonza combines computer models with experiments to predict a molecule’s PK, and whether solubility problems might need solving.
Swiss CMDO Lonza said it will expand its Early Development Services (EDS) offering into North America with a new laboratory in Cambridge, Massachusetts, set to open in...
